A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Enrolling
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD)
and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by
intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD).
Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part
B: 12 months.
Trial at a Glance
- Trial ID
- ALN-APP-001
- Condition
- Alzheimer's Disease
- Drug/Treatment
- ALN-APP
- Does this trial use a placebo?
- Yes
- Trial Type
- Interventional
- Number of Participants
- 60 participants
- Trial dates
- February 4, 2022 - March 1, 2029
For more information:NCT05231785
Who can participate?
AGE
18+ Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
No
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
